Saturday, July 11, 2026

Drug profile · INN

laquinimod

laquinimod (NERVENTRA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH.

EMA: refused Nervous system (N07) N07
Patents linked 14
Pipeline programs 10
News articles 0
Drug details — laquinimod
Class
Nervous system (N07)
Route
Patents
14
Programs
10
Data quality
0.89

Quick answer

laquinimod (NERVENTRA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH.

Key facts

INN laquinimod
Brand NERVENTRA
Therapeutic class Nervous system (N07)
ATC code N07

Approval history

Authority Status Date
EMA refused

Pipeline programs

  1. Laquinimod Phase 3 · Teva Pharma · Multiple Sclerosis
  2. Laquinimod Phase 3 · Teva Pharma · Relapsing Multiple Sclerosis
  3. Laquinimod Phase 3 · Teva Pharma · Relapsing Remitting Multiple Sclerosis
  4. Laquinimod Phase 2 · Teva Pharma · Lupus Arthritis
  5. Laquinimod Phase 2 · Teva Pharma · Crohn's Disease
  6. Laquinimod Phase 2 · Teva Pharma · Huntington's Disease
  7. Laquinimod Phase 2 · Teva Pharma · Lupus Nephritis
  8. Laquinimod 0.6 Phase 2 · Teva Pharma · Relapsing Multiple Sclerosis

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)
  1. US 9340307

    Stable laquinimod preparations

    Expires 2036-05-12T00:00:00.000Z

    granted
  2. US 9233927

    Crystals of laquinimod sodium and improved process for the manufacture thereof

    Expires 2036-01-07T00:00:00.000Z

    granted
  3. US 9161936

    Laquinimod for treatment of GABA mediated disorders

    Expires 2035-10-15T00:00:00.000Z

    granted
  4. US 9161935

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

    Expires 2035-10-15T00:00:00.000Z

    granted
  5. US 8975279

    Amine salts of laquinimod

    Expires 2035-03-05T00:00:00.000Z

    granted
  6. US 8889661

    Treatment of lupus nephritis using laquinimod

    Expires 2034-11-13T00:00:00.000Z

    granted
  7. US 8673322

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires 2034-03-13T00:00:00.000Z

    granted
  8. US 8647646

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires 2034-02-06T00:00:00.000Z

    granted
  9. US 8598203

    Treatment of Crohn's disease with laquinimod

    Expires 2033-11-28T00:00:00.000Z

    granted
  10. US 8545885

    Stable laquinimod preparations

    Expires 2033-09-26T00:00:00.000Z

    granted
  11. US 8383645

    Stable laquinimod preparations

    Expires 2033-02-21T00:00:00.000Z

    granted
  12. US 8178127

    Stable laquinimod preparations

    Expires 2032-05-10T00:00:00.000Z

    granted
  13. US 7989473

    Stable laquinimod preparations

    Expires 2031-07-28T00:00:00.000Z

    granted
  14. US 7884208

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires 2031-02-03T00:00:00.000Z

    granted

Frequently asked questions

What is laquinimod?

laquinimod (NERVENTRA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH.

What is the brand name for laquinimod?

NERVENTRA is a marketed brand name for laquinimod. Check FDA Drugs@FDA for the current US label holder and prescribing information.